Open AccessDevelopments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008
Author(s) -
Michel Ducreux
Publication year - 2009
Publication title -
clinical and experimental gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.113
H-Index - 30
ISSN - 1178-7023
DOI - 10.2147/ceg.s3908
Subject(s) - medicine , cetuximab , bevacizumab , irinotecan , oxaliplatin , colorectal cancer , capecitabine , oncology , tolerability , chemotherapy , cancer , adverse effect
Treatment for metastatic colorectal cancer (mCRC), employing various schedules, combinations, and regimens utilizing 5-fluorouracil (5-FU), irinotecan, oxaliplatin, capecitabine, bevacizumab, and cetuximab, currently achieves an overall survival that extends to approximately two years. Major questions regarding optimal management of mCRC await resolution.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom